Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/168—Steroids
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/184—Hormones
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics

Definitions

• BMI body mass index
• the invention therefore proposes to provide phytoecdysones in a composition intended for the mammal, or in a medicinal composition, for the purpose of suppressing or preventing the appearance of the metabolic syndrome.
• the decrease in fat already acquired may allow some individuals to no longer suffer from the metabolic syndrome. Indeed, the decrease in fat mass indirectly affects many of the symptoms associated with the metabolic syndrome, including abdominal obesity, blood glucose and atherogenic dyslipidemia. In addition, it can also have a preventive action on the development of the syndrome metabolic rate in overweight people, allowing a decrease in fat already gained and / or avoiding additional intake.
• the subject of the invention is also an extract of food plants enriched with phytoecdysones.
• said extract comprises at least 1% and preferably between 1% and 7%, preferably between 1.5% and 3% and even more preferably 2% by weight of phytoecdysones.
• FIG. 2 Graph representing the percentage of epididymal adipocytes (% TAE in mg / g BW) as a function of the diet at which the mice are subjected;
• FIG. 4 Graph representing the diameter of the adipocytes, in microns, as a function of the treatment administered to the mice subjected to the Lard diet;
• the ethanol extract is filtered through miracloth TM, evaporated to dryness and taken up with 400 ml of absolute ethanol, leaving an abundant insoluble residue.
• the ethanolic fraction is filtered or centrifuged and then dried.
• a second extraction is then carried out with ethanol (400 ml of ethanol) for 2.5 minutes in the microwave still at medium power (800 W).
• the two extraction methods make it possible to obtain between 150 and 200 milligrams of phytoecdysones per kilogram of treated quinoa seeds, of which 85-90% correspond to 20-hydroxyecdysone, and the remainder to ecdysteroids of very similar structure.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Food Science & Technology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Animal Husbandry (AREA)
• Botany (AREA)
• Nutrition Science (AREA)
• Zoology (AREA)
• Biotechnology (AREA)
• Hematology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Alternative & Traditional Medicine (AREA)
• Obesity (AREA)
• Endocrinology (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Diabetes (AREA)
• Child & Adolescent Psychology (AREA)
• Medicines Containing Plant Substances (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Steroid Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39473912

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (5)

Family Cites Families (14)

• 2007
  • 2007-11-30 FR FR0759478A patent/FR2924346B1/fr active Active
• 2008
  • 2008-11-19 EP EP08856497.6A patent/EP2217255B1/fr active Active
  • 2008-11-19 JP JP2010535430A patent/JP2011504921A/ja active Pending
  • 2008-11-19 CA CA2706821A patent/CA2706821A1/fr not_active Abandoned
  • 2008-11-19 CN CN200880118514.XA patent/CN102231986B/zh active Active
  • 2008-11-19 US US12/745,315 patent/US8236359B2/en active Active
  • 2008-11-19 RU RU2010126625/15A patent/RU2491083C2/ru active
  • 2008-11-19 PL PL08856497T patent/PL2217255T3/pl unknown
  • 2008-11-19 WO PCT/FR2008/052088 patent/WO2009071804A2/fr not_active Ceased
  • 2008-11-19 BR BRPI0820455A patent/BRPI0820455B8/pt active IP Right Grant
  • 2008-11-19 ES ES08856497T patent/ES2747932T3/es active Active
  • 2008-11-19 AU AU2008332981A patent/AU2008332981B2/en active Active

Also Published As

Similar Documents

Legal Events